Cargando…

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia

AIM: Results from clinical trials support the use of oral antipsychotics for treatment of early or first‐episode psychosis in patients with schizophrenia. This paper will review literature on the advantages of early initiation of treatment for schizophrenia and the clinical benefits of early use of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stevens, Georgia L., Dawson, Gail, Zummo, Jacqueline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054869/ https://www.ncbi.nlm.nih.gov/pubmed/26403538 http://dx.doi.org/10.1111/eip.12278

Ejemplares similares

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
por: Kaplan, Gabriel, et al.
Publicado: (2013)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
por: Samalin, Ludovic, et al.
Publicado: (2016)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia
por: Viala, Annie, et al.
Publicado: (2012)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics
por: Kheloussi, Steven, et al.
Publicado: (2022)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2019)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini, Francesco, et al.
Publicado: (2019)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
por: Milz, Ruth, et al.
Publicado: (2023)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
por: Tascón Guerra, M.F., et al.
Publicado: (2022)

Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia
por: Brown, Brianne, et al.
Publicado: (2019)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

T167. QUALITATIVE DIFFERENCES IN LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS AMONG SCHIZOPHRENIA PATIENTS
por: Karakasi, Valeria, et al.
Publicado: (2020)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
por: Citrome, Leslie, et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
por: Bhatta, Madhav P., et al.
Publicado: (2021)

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
por: Pae, Chi-Un, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review
por: Ma, Ning, et al.
Publicado: (2023)

The effect of long-acting injectable antipsychotics on QRISK3 in patients with bipolar disorder and schizophrenia
por: Erbasan, V., et al.
Publicado: (2023)

Guidance on the clinical understanding and use of long‐acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements
por: Wong, Michael Ming Cheuk, et al.
Publicado: (2021)

Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?
por: Paton, Carol, et al.
Publicado: (2022)

Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2022)

Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia
por: Huang, Cheng-Yi, et al.
Publicado: (2021)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
por: Ohnishi, Takashi, et al.
Publicado: (2021)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
por: Přikryl, Radovan, et al.
Publicado: (2012)

PM399. Attitudes toward antipsychotic long-acting injections among patients with Schizophrenia in Japan.
por: Kudo, Shuhei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2qb1qtjoacp28udmgs1ardrfn1